Next, to compare the efficacy of ADC targeting CCRL2 with the efficacy of ADCs against other targets, PBD-conjugated ADCs targeting the well described AML targets CD33, and CD123 were developed (Supplementary Figs. 1E-F). Here, CD33 is linked to acute myeloid leukemia.